Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 11/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 10/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 10/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8320146 | 0.89 | GNAO1 (0.40) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL9385178 | 0.87 | GNAO1 (0.43) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL9388852 | 0.85 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL9388207 | 0.85 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL9383352 | 0.85 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL9383347 | 0.85 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL9385199 | 0.85 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL9384209 | 0.85 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL9389327 | 0.85 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL382836 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0135349-B1 | CONDENSED SEVEN-MEMBERED RING COMPOUNDS AND THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1988-11-02 | — | — | EP | claimed |
| US-4548932-A | ANGIOTENSIN INHIBITOR, HYPOTENSIVE AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-22 | — | — | US | claimed |
| EP-0135349-A1 | Condensed seven-membered ring compounds and their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-03-27 | — | — | EP | claimed |
| US-20140275063-A1 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| EP-2755975-A1 | NEW ENZYME INHIBITOR COMPOUNDS | Proximagen Limited (GB) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013038189-A1 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LTD. (GB) | 2013-03-21 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| CN-1245402-C | indole derivatives, process for their preparation, pharmaceutical compositions containing them and their use | ASTRAZENECA AB (SE) | 2006-03-15 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| CN-1167422-C | Quinazoline derivatives as angiogenesis inhibitors | — | 2004-09-22 | — | — | CN | disclosed |
| CN-1468230-A | Compound (I) | — | 2004-01-14 | — | — | CN | disclosed |
| CN-1446214-A | Cinnoline compounds | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | CN | disclosed |
| CN-1346271-A | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA UK LTD (SE) | 2002-04-24 | — | — | CN | disclosed |
| EP-0604494-A1 | 5-HT 4? RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-06 | — | — | EP | disclosed |
| EP-0135349-B1 | CONDENSED SEVEN-MEMBERED RING COMPOUNDS AND THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1988-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275063-A1 | NEW ENZYME INHIBITOR COMPOUNDS | XDH, MAOB, MAOA | GNAO1 2692/4885GNAI3 4083/4885GNAI1 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.